Harnessing IGF-1 and IL-2 as biomarkers for calcineurin activity to tailor optimal FK506 dosage in α-synucleinopathies. Alzforum, 15 Dec 2023 Zaichick S, Caraveo G. Front Mol Biosci. 2023;10:1292555. Epub 2023 Nov 29 PubMed.